Quality of Life in Uveal Melanoma Patients in Ireland: A Single-Centre Survey.
EORTC QLQ-C30
EORTC QLQ-OPT30
Quality of life
Uveal melanoma
Journal
Ocular oncology and pathology
ISSN: 2296-4681
Titre abrégé: Ocul Oncol Pathol
Pays: Switzerland
ID NLM: 101656139
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
27
02
2019
accepted:
22
06
2019
entrez:
8
4
2020
pubmed:
8
4
2020
medline:
8
4
2020
Statut:
ppublish
Résumé
Uveal melanoma and its treatment can influence the physical and psychological well-being of patients in a way that differs from other cancers. Factors influencing quality of life (QOL) include visual impairment, changes in appearance, day-to-day functioning, ocular discomfort, and worry regarding disease recurrence. We aimed to study both general and disease-specific QOL in uveal melanoma patients in Ireland and compare QOL between a plaque radiotherapy group and an enucleation treatment group. This information was sought to enhance our understanding of QOL issues for uveal melanoma patients, in the context of improving care and providing appropriate psychosocial support. The European Organisation for Research and Treatment of Cancer (EORTC) QOL questionnaires QLQ-C30 and QLQ-OPT30 were completed by patients with uveal melanoma treated by enucleation or brachytherapy. 138 of 206 patients completed the questionnaires. There was no significant difference in QOL scores between treatment groups. Thirty-two percent of patients reported concerns about tumour recurrence elsewhere in the body. The brachytherapy group had a significantly higher "role functioning" score ( There was no significant difference in reported QOL between treatment groups. Our data identified a number of vulnerable patient subgroups. By anticipating which patients are more likely to suffer in terms of certain aspects of their QOL, we are better able to provide appropriate and timely psychosocial support.
Sections du résumé
BACKGROUND
BACKGROUND
Uveal melanoma and its treatment can influence the physical and psychological well-being of patients in a way that differs from other cancers. Factors influencing quality of life (QOL) include visual impairment, changes in appearance, day-to-day functioning, ocular discomfort, and worry regarding disease recurrence.
OBJECTIVE
OBJECTIVE
We aimed to study both general and disease-specific QOL in uveal melanoma patients in Ireland and compare QOL between a plaque radiotherapy group and an enucleation treatment group. This information was sought to enhance our understanding of QOL issues for uveal melanoma patients, in the context of improving care and providing appropriate psychosocial support.
METHOD
METHODS
The European Organisation for Research and Treatment of Cancer (EORTC) QOL questionnaires QLQ-C30 and QLQ-OPT30 were completed by patients with uveal melanoma treated by enucleation or brachytherapy.
RESULTS
RESULTS
138 of 206 patients completed the questionnaires. There was no significant difference in QOL scores between treatment groups. Thirty-two percent of patients reported concerns about tumour recurrence elsewhere in the body. The brachytherapy group had a significantly higher "role functioning" score (
CONCLUSIONS
CONCLUSIONS
There was no significant difference in reported QOL between treatment groups. Our data identified a number of vulnerable patient subgroups. By anticipating which patients are more likely to suffer in terms of certain aspects of their QOL, we are better able to provide appropriate and timely psychosocial support.
Identifiants
pubmed: 32258017
doi: 10.1159/000501692
pii: oop-0006-0099
pmc: PMC7109402
doi:
Types de publication
Journal Article
Langues
eng
Pagination
99-106Informations de copyright
Copyright © 2019 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
There were no conflicts of interest.
Références
Acta Ophthalmol. 2018 Jun;96(4):e421-e426
pubmed: 29369538
J Contemp Brachytherapy. 2017 Oct;9(5):453-465
pubmed: 29204166
Am J Ophthalmol. 2018 Sep;193:230-251
pubmed: 29555484
Front Public Health. 2015 Apr 27;2:214
pubmed: 25964922
Eye (Lond). 2016 Dec;30(12):1598-1605
pubmed: 27589051
Eye (Lond). 2000 Dec;14(Pt 6):839-46
pubmed: 11584839
J Oncol. 2018 Mar 20;2018:5253109
pubmed: 29755525
J Health Soc Behav. 2018 Mar;59(1):74-93
pubmed: 29320638
Ophthalmology. 2002 Dec;109(12):2197-206
pubmed: 12466159
J Clin Epidemiol. 2016 Jan;69:79-88
pubmed: 26327487
Clin Ophthalmol. 2016 Oct 25;10:2113-2119
pubmed: 27822007
Arch Ophthalmol. 1999 Apr;117(4):461-7
pubmed: 10206573
Eur J Cancer. 2019 Jan;107:153-163
pubmed: 30576971
Arch Ophthalmol. 2006 Feb;124(2):226-38
pubmed: 16476893
Arch Ophthalmol. 2006 Dec;124(12):1684-93
pubmed: 17159027
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Arch Ophthalmol. 2008 Oct;126(10):1413-8
pubmed: 18852420
Clin Trials. 2011 Oct;8(5):661-73
pubmed: 22013172
Can J Ophthalmol. 2017 Apr;52(2):181-185
pubmed: 28457288
Ocul Oncol Pathol. 2019 Apr;5(3):195-204
pubmed: 31049328